Latest Titan Pharma Inc (TTNP) Headlines Titan Ph
Post# of 62
Posted On: 03/11/2014 9:57:27 PM
Latest Titan Pharma Inc (TTNP) Headlines
Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Marketwire - Mon Mar 03, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Spectra7 Announces Promotion Of Melissa Chee To Vice President Of Corporate Marketing And Product Management
PR Newswire - Tue Feb 04, 8:00AM CST
(TSX-V:SEV) Spectra7 Microsystems Inc. ("Spectra7"), a high performance analog semiconductor company delivering unprecedented speed, resolution and signal fidelity to consumer and wireless infrastructure products, today announced that Melissa Chee has been promoted to Vice President of Corporate Marketing and Product Management for the Company.
SecurityMetrics PCI Suite Named Finalist in Info Security Products Guide Global Excellence Awards
PR Newswire - Thu Jan 16, 12:18PM CST
Info Security Products Guide, the industry's leading information security research and advisory guide, has named SecurityMetrics PCI Suite a finalist for the 10th Annual 2014 Global Excellence Awards in the PCI Compliance category. These prestigious global awards recognize security and IT vendors with advanced products and solutions that help set the bar higher for others in all areas of security and technology.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application
Marketwire - Mon Dec 23, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the receipt of the official minutes (the "Minutes") from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine(R), an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine. Titan and Braeburn proposed the revised indication following a review of the FDA's comments on the briefing material and to address one of the primary concerns in the CRL regarding dose adequacy among the original study population (newly inducted patients maintained at 12-16 mg SL BPN/day). The FDA maintained the need for clinical data in this patient population as a requirement for approval, stipulating that the study "need not be large," "be adequate and well-controlled," and "must support labeling for the duration of treatment (6 months)." Titan and Braeburn are working with experts in the field to develop a clinical study design for submission to the FDA within the next few weeks.
Cambridge University Press picks DayNine Consulting management tool
M2 - Wed Dec 18, 8:25AM CST
Workday (NYSE: WDAY) services partner DayNine Consulting said it was selected by Cambridge University Press to deploy its Workday Human Capital Management solution.
Titan Pharmaceuticals Announces Third Quarter 2013 Financial Results
Marketwire - Thu Nov 14, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the third quarter ended September 30, 2013.
Exclusive Insight on FITX, TTNP and NTEK
ACCESSWIRE - Thu Nov 14, 4:37AM CST
Creative Edge Nutrition, Inc. (OTC:FITX), Titan Pharmaceuticals Inc. (OTC:TTNP) and NanoTech Entertainment, Inc. (OTC:NTEK) have been added to our watch list.
Titan Pharmaceuticals Announces $5 Million Equity Investment and Restructuring of Probuphine Partnership
Marketwire - Wed Nov 13, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced a $5 million equity investment by Braeburn Pharmaceuticals Sprl and a restructuring of certain terms of the License Agreement for commercialization of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence, primarily to adjust the timing and amount of the approval and sales milestones. The agreements reflect Titan's need to address its cash flow requirements through next year given the generally uncertain nature of the regulatory process with respect to both timing and outcome. The agreements also address Braeburn's recognition of the potential impact of the delay in the regulatory approval process, as well as the changing market for opioid addiction treatments, on its investment in Probuphine and enable Braeburn to continue advancing the regulatory process and support the commercialization of Probuphine, if approved.
Exclusive Insight on TTNP, NHUR, AMZG and FNRC
ACCESSWIRE - Tue Nov 12, 9:15AM CST
Titan Pharmaceuticals Inc. (OTC:TTNP), Supernova Energy, Inc. (OTC:NHUR), American Eagle Energy Corporation (OTC:AMZG) and 1st NRG Corp. (OTC:FNRC) have been added to our watch list.
Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2013 Financial Results
Marketwire - Fri Nov 08, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1:00pm ET/10:00am PT on Friday, November 15, 2013. Titan will provide the Company's financial results as of September 30, 2013. The call will be hosted by Sunil Bhonsle, president, Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer, Brian Crowley, vice president of finance and Marc Rubin, M.D., executive chairman.
In Depth Coverage on SCRC, TTNP, EWSI and SKTO
ACCESSWIRE - Wed Nov 06, 12:42AM CST
ScripsAmerica Inc (OTC:SCRC), Titan Pharmaceuticals Inc (OTC:TTNP), E-Waste Systems Inc (OTC:EWSI) and SK3 Group Inc. (OTC:SKTO) have been added to our watch list.
Small Cap Stocks In Focus: SKTO, TTNP and MAMS
ACCESSWIRE - Thu Oct 31, 12:18AM CDT
SK3 Group Inc (OTC:SKTO), Titan Pharmaceuticals Inc (OTC:TTNP) and MAMS Software Group Inc (OTC:MAMS) are today's small cap stocks in focus.
Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine
Marketwire - Wed Sep 04, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the submission of a Type B meeting request to the U.S. Food and Drug Administration (FDA) to discuss Probuphine(R), the company's investigational subdermal implant designed to deliver continuous, blood levels of buprenorphine for six months following a single treatment.
Titan Pharmaceuticals Announces Second Quarter 2013 Financial Results
Marketwire - Wed Aug 14, 3:52PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the second quarter ended June 30, 2013.
Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction
Marketwire - Tue Aug 13, 4:03PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that data from its previously completed and announced Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine(R), evaluating the safety and efficacy of its subdermal implant for the maintenance treatment of opioid dependence in adult patients, were published online in the journal Addiction. The paper is expected to appear in a future print issue of the journal.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 6:51PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that its management will host a conference call at 10:00am PT / 1:00pm ET on Thursday, August 15, 2013 and provide the Company's financial results as of June 30, 2013. Highlights of the second quarter financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals
Marketwire - Wed May 29, 3:05PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine(R), a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine following a single treatment. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant additional clinical work or a material change to the product label will be required by the U.S. Food and Drug Administration (FDA) as a condition to approval of the New Drug Application (NDA) or if the NDA is not approved by June 30, 2014.
Titan Pharmaceuticals Inc swings to net income of USD6.0m for Q1 2013
M2 - Thu May 16, 8:30AM CDT
Biopharmaceutical company Titan Pharmaceuticals Inc (OTCBB:TTNP) stated on Wednesday its net income of USD6.0m (USD0.08 per share) for the first quarter ended 31 March 2013.
Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Marketwire - Mon Mar 03, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
Spectra7 Announces Promotion Of Melissa Chee To Vice President Of Corporate Marketing And Product Management
PR Newswire - Tue Feb 04, 8:00AM CST
(TSX-V:SEV) Spectra7 Microsystems Inc. ("Spectra7"), a high performance analog semiconductor company delivering unprecedented speed, resolution and signal fidelity to consumer and wireless infrastructure products, today announced that Melissa Chee has been promoted to Vice President of Corporate Marketing and Product Management for the Company.
SecurityMetrics PCI Suite Named Finalist in Info Security Products Guide Global Excellence Awards
PR Newswire - Thu Jan 16, 12:18PM CST
Info Security Products Guide, the industry's leading information security research and advisory guide, has named SecurityMetrics PCI Suite a finalist for the 10th Annual 2014 Global Excellence Awards in the PCI Compliance category. These prestigious global awards recognize security and IT vendors with advanced products and solutions that help set the bar higher for others in all areas of security and technology.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application
Marketwire - Mon Dec 23, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the receipt of the official minutes (the "Minutes") from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine(R), an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine. Titan and Braeburn proposed the revised indication following a review of the FDA's comments on the briefing material and to address one of the primary concerns in the CRL regarding dose adequacy among the original study population (newly inducted patients maintained at 12-16 mg SL BPN/day). The FDA maintained the need for clinical data in this patient population as a requirement for approval, stipulating that the study "need not be large," "be adequate and well-controlled," and "must support labeling for the duration of treatment (6 months)." Titan and Braeburn are working with experts in the field to develop a clinical study design for submission to the FDA within the next few weeks.
Cambridge University Press picks DayNine Consulting management tool
M2 - Wed Dec 18, 8:25AM CST
Workday (NYSE: WDAY) services partner DayNine Consulting said it was selected by Cambridge University Press to deploy its Workday Human Capital Management solution.
Titan Pharmaceuticals Announces Third Quarter 2013 Financial Results
Marketwire - Thu Nov 14, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the third quarter ended September 30, 2013.
Exclusive Insight on FITX, TTNP and NTEK
ACCESSWIRE - Thu Nov 14, 4:37AM CST
Creative Edge Nutrition, Inc. (OTC:FITX), Titan Pharmaceuticals Inc. (OTC:TTNP) and NanoTech Entertainment, Inc. (OTC:NTEK) have been added to our watch list.
Titan Pharmaceuticals Announces $5 Million Equity Investment and Restructuring of Probuphine Partnership
Marketwire - Wed Nov 13, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced a $5 million equity investment by Braeburn Pharmaceuticals Sprl and a restructuring of certain terms of the License Agreement for commercialization of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence, primarily to adjust the timing and amount of the approval and sales milestones. The agreements reflect Titan's need to address its cash flow requirements through next year given the generally uncertain nature of the regulatory process with respect to both timing and outcome. The agreements also address Braeburn's recognition of the potential impact of the delay in the regulatory approval process, as well as the changing market for opioid addiction treatments, on its investment in Probuphine and enable Braeburn to continue advancing the regulatory process and support the commercialization of Probuphine, if approved.
Exclusive Insight on TTNP, NHUR, AMZG and FNRC
ACCESSWIRE - Tue Nov 12, 9:15AM CST
Titan Pharmaceuticals Inc. (OTC:TTNP), Supernova Energy, Inc. (OTC:NHUR), American Eagle Energy Corporation (OTC:AMZG) and 1st NRG Corp. (OTC:FNRC) have been added to our watch list.
Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2013 Financial Results
Marketwire - Fri Nov 08, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1:00pm ET/10:00am PT on Friday, November 15, 2013. Titan will provide the Company's financial results as of September 30, 2013. The call will be hosted by Sunil Bhonsle, president, Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer, Brian Crowley, vice president of finance and Marc Rubin, M.D., executive chairman.
In Depth Coverage on SCRC, TTNP, EWSI and SKTO
ACCESSWIRE - Wed Nov 06, 12:42AM CST
ScripsAmerica Inc (OTC:SCRC), Titan Pharmaceuticals Inc (OTC:TTNP), E-Waste Systems Inc (OTC:EWSI) and SK3 Group Inc. (OTC:SKTO) have been added to our watch list.
Small Cap Stocks In Focus: SKTO, TTNP and MAMS
ACCESSWIRE - Thu Oct 31, 12:18AM CDT
SK3 Group Inc (OTC:SKTO), Titan Pharmaceuticals Inc (OTC:TTNP) and MAMS Software Group Inc (OTC:MAMS) are today's small cap stocks in focus.
Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine
Marketwire - Wed Sep 04, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the submission of a Type B meeting request to the U.S. Food and Drug Administration (FDA) to discuss Probuphine(R), the company's investigational subdermal implant designed to deliver continuous, blood levels of buprenorphine for six months following a single treatment.
Titan Pharmaceuticals Announces Second Quarter 2013 Financial Results
Marketwire - Wed Aug 14, 3:52PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the second quarter ended June 30, 2013.
Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction
Marketwire - Tue Aug 13, 4:03PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that data from its previously completed and announced Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine(R), evaluating the safety and efficacy of its subdermal implant for the maintenance treatment of opioid dependence in adult patients, were published online in the journal Addiction. The paper is expected to appear in a future print issue of the journal.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 6:51PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that its management will host a conference call at 10:00am PT / 1:00pm ET on Thursday, August 15, 2013 and provide the Company's financial results as of June 30, 2013. Highlights of the second quarter financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals
Marketwire - Wed May 29, 3:05PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine(R), a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine following a single treatment. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant additional clinical work or a material change to the product label will be required by the U.S. Food and Drug Administration (FDA) as a condition to approval of the New Drug Application (NDA) or if the NDA is not approved by June 30, 2014.
Titan Pharmaceuticals Inc swings to net income of USD6.0m for Q1 2013
M2 - Thu May 16, 8:30AM CDT
Biopharmaceutical company Titan Pharmaceuticals Inc (OTCBB:TTNP) stated on Wednesday its net income of USD6.0m (USD0.08 per share) for the first quarter ended 31 March 2013.
(0)
(0)Titan Pharmaceuticals, Inc. (TTNP) Stock Research Links
Scroll down for more posts ▼